Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids

Background: Selective progesterone receptor modulator ulipristal acetate (UPA) is a drug used in management of symptomatic myomas. It was observed that the response to UPA treatment in uterine myomas varied amongst patients. An attempt was thus made at establishing predictive factors conducive to better reaction to treatment with UPA. The aim of this study was to assess the efficacy of UPA treatment in women with myomas, depending on pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Materials and methods: The study included patients with one to four myomas. The UPA treatment was a preparation stage for surgical treatment in all patients. The study group was divided into the subgroups according to pretreatment myomas’ volume, number of myomas, age of patients, estrogenic status of women, and pretreatment blood flow in uterine arteries. Results: A better effect of reduction in size of myomas after UPA treatment was noted when pretreatment myomas’ volume was lower than 30 cm3. A significant reduction in fibroids’ size was observed after UPA therapy independently of the number of myomas and age of patients. A good response after the UPA therapy was observed when pretreatment estradiol concentration was below 50 pg/mL and when uterine artery resistance index (RI) was above 0.8. Conclusions: Our research demonstrates that treatment with ulipristal acetate is an efficient method in preoperative preparation of patients with uterine fibroids. The most important factor of positive response to UPA therapy is myoma volume. The number of myomas and patient’s age do not interfere with effects of UPA therapy. Pretreatment estradiol concentration is significant, yet secondary for the effects of therapy. The UPA therapy has no impact on blood flow in the uterine arteries and no adverse influence on estradiol concentrations.

[1]  J. Donnez,et al.  Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. , 2018, Reproductive biomedicine online.

[2]  A. Ebert,et al.  Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate , 2018, BioMed research international.

[3]  A. Paoletti,et al.  Vilaprisan for treating uterine fibroids , 2018, Expert opinion on investigational drugs.

[4]  M. K. Kim,et al.  Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[5]  J. Segars,et al.  Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. , 2018, Obstetrics and gynecology.

[6]  W. Catherino,et al.  A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma , 2018, BioMed research international.

[7]  S. Ferrero,et al.  Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids , 2018, Expert opinion on drug metabolism & toxicology.

[8]  M. K. Kim,et al.  Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist , 2017, Obstetrics & gynecology science.

[9]  J. Donnez,et al.  Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate , 2016, Expert opinion on drug safety.

[10]  M. Powell,et al.  Esmya® and the PEARL studies: A review , 2016, Women's health.

[11]  Qiwei Yang,et al.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development , 2016, Reproductive Sciences.

[12]  J. Donnez,et al.  The place of selective progesterone receptor modulators in myoma therapy. , 2016, Minerva ginecologica.

[13]  J. Donnez,et al.  Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators , 2015, Current opinion in obstetrics & gynecology.

[14]  I. Osterloh,et al.  Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. , 2015, Fertility and sterility.

[15]  Aamir T Khan,et al.  Uterine fibroids: current perspectives , 2014, International journal of women's health.

[16]  J. Segars,et al.  The impact and management of fibroids for fertility: an evidence-based approach. , 2012, Obstetrics and gynecology clinics of North America.

[17]  I. Osterloh,et al.  Ulipristal acetate versus leuprolide acetate for uterine fibroids. , 2012, The New England journal of medicine.

[18]  I. Osterloh,et al.  Ulipristal acetate versus placebo for fibroid treatment before surgery. , 2012, The New England journal of medicine.

[19]  I. Cameron,et al.  Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. , 2008, The Journal of clinical endocrinology and metabolism.

[20]  V. Markussis,et al.  Doppler‐ultrasound as a predictor of uterine fibroid response to GnRH therapy , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[21]  I. Szabó,et al.  Color Doppler ultrasonography in the differentiation of uterine sarcomas from uterine leiomyomas. , 2002, European journal of gynaecological oncology.

[22]  O. Oyesanya,et al.  Altered uterine artery blood flow impedance after danazol therapy: possible mode of action in dysfunctional uterine bleeding. , 1999, Fertility and sterility.

[23]  S. Yen,et al.  The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. , 1994, American journal of obstetrics and gynecology.

[24]  F. Ghezzi,et al.  Management of Asymptomatic Submucous Myomas in Women of Reproductive Age: A Consensus Statement from the Global Congress on Hysteroscopy Scientific Committee. , 2019, Journal of minimally invasive gynecology.

[25]  E. A. Kogan,et al.  [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators]. , 2017, Arkhiv patologii.

[26]  D. Samulak,et al.  Clinical usefulness of evaluation of quality parameters of blood flow: pulsation index and resistance index in the uterine arteries in the initial differential diagnostics of pathology within the endometrium. , 2010, European journal of gynaecological oncology.